Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIg in Glycine Receptor Antibody Positive SPS
NCT03749096Phase 3Withdrawn
- Sponsor
- Mayo Clinic
- Start
- Dec 2018
- Primary completion
- Apr 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in stiff person syndrome (SPS) comparing Intravenous immunoglobulin with Placebo (2 arms). Primary endpoints: Change in Distribution-of-stiffness index at 11 weeks and Change in Heightened-sensitivity scale at 11 weeks. Planned start Dec 2018; status: withdrawn.
02
Drugs
intravenous immunoglobulin G
03
Conditions
stiff person syndrome (SPS)
Beyond the preview
Go deeper on NCT03749096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03749096.